Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Tuesday 15 September, 2009

Lipoxen PLC

Additional Listing

RNS Number : 1047Z
Lipoxen PLC
15 September 2009
 



Lipoxen PLC

('Lipoxen' or 'the Company')


Additional listing


London, UK, 15 September 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 52,000 ordinary shares of 0.5p each (the 'New Ordinary Shares').


The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.


It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 16 September 2009.


Enquiries 


Lipoxen plc

+44 (0)20 7691 3583 

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 




Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  




Buchanan Communications

+44 (0)20 7466 5000

Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen





This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISEALNSFADNEFE